Hungarian Society of Urology
  
  
Category search
DOI
Journal date
Title
Author
Content
Related Sites

New treatment options for non-metastatic castration resistant (nmCRPC) prostate cancer

DOI: 10.22591/magyurol.2020.2.geczil.58

Authors:
Géczi Lajos dr.
Országos Onkológiai Intézet, Urogenitalis Tumorok és Klinikai Farmakológiai Osztály, Budapest (osztályvezető: Géczi Lajos dr.)

Summary

In this rewiev the author presents the results of SPARTAN, PROSPER and ARAMIS studies in nmCRPC. In the main clinical endponds (MFS, PFS, OS) apalutamid, enzalutamid and darolutamid in combination with androgen deprivation therapy (ADT) showed significant advantage compare to placebo and ADT. After these phase III clinical studies new standard treatment possibilities are available for clinicians in nmCRPC.

LAPSZÁM: MAGYAR UROLÓGIA | 2020 | 32. ÉVFOLYAM, 2. SZÁM

click here to read the full article